Activation of the integrated stress response confers vulnerability to mitoribosome-targeting antibiotics in melanoma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378050%3A_____%2F21%3A00555718" target="_blank" >RIV/68378050:_____/21:00555718 - isvavai.cz</a>
Result on the web
<a href="https://rupress.org/jem/article/218/9/e20210571/212494/Activation-of-the-integrated-stress-response" target="_blank" >https://rupress.org/jem/article/218/9/e20210571/212494/Activation-of-the-integrated-stress-response</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1084/jem.20210571" target="_blank" >10.1084/jem.20210571</a>
Alternative languages
Result language
angličtina
Original language name
Activation of the integrated stress response confers vulnerability to mitoribosome-targeting antibiotics in melanoma
Original language description
The ability to adapt to environmental stress, including therapeutic insult, contributes to tumor evolution and drug resistance. In suboptimal conditions, the integrated stress response (ISR) promotes survival by dampening cytosolic translation. We show that ISR-dependent survival also relies on a concomitant up-regulation of mitochondrial protein synthesis, a vulnerability that can be exploited using mitoribosome-targeting antibiotics. Accordingly, such agents sensitized to MAPK inhibition, thus preventing the development of resistance in BRAFV600E melanoma models. Additionally, this treatment compromised the growth of melanomas that exhibited elevated ISR activity and resistance to both immunotherapy and targeted therapy. In keeping with this, pharmacological inactivation of ISR, or silencing of ATF4, rescued the antitumoral response to the tetracyclines. Moreover, a melanoma patient exposed to doxycycline experienced complete and long-lasting response of a treatment-resistant lesion. Our study indicates that the repurposing of mitoribosome-targeting antibiotics offers a rational salvage strategy for targeted therapy in BRAF mutant melanoma and a therapeutic option for NRAS-driven and immunotherapy-resistant tumors.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10608 - Biochemistry and molecular biology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of Experimental Medicine
ISSN
0022-1007
e-ISSN
1540-9538
Volume of the periodical
218
Issue of the periodical within the volume
9
Country of publishing house
US - UNITED STATES
Number of pages
27
Pages from-to
e20210571
UT code for WoS article
000704364600005
EID of the result in the Scopus database
—